OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.202
EU - Europa 5.576
AS - Asia 5.554
SA - Sud America 819
AF - Africa 169
Continente sconosciuto - Info sul continente non disponibili 155
OC - Oceania 33
Totale 22.508
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.966
IT - Italia 1.649
SG - Singapore 1.574
CN - Cina 1.331
GB - Regno Unito 963
IE - Irlanda 833
VN - Vietnam 644
HK - Hong Kong 626
BR - Brasile 589
DE - Germania 513
SE - Svezia 368
BD - Bangladesh 353
FR - Francia 253
RU - Federazione Russa 208
FI - Finlandia 204
IN - India 175
ID - Indonesia 150
KR - Corea 145
CA - Canada 126
UA - Ucraina 113
TR - Turchia 94
AR - Argentina 79
JP - Giappone 67
BG - Bulgaria 63
IQ - Iraq 63
NL - Olanda 63
MX - Messico 58
PL - Polonia 51
LT - Lituania 46
ES - Italia 42
CO - Colombia 41
TW - Taiwan 41
CL - Cile 39
ZA - Sudafrica 35
EG - Egitto 34
PK - Pakistan 34
MY - Malesia 31
AU - Australia 30
BE - Belgio 30
CZ - Repubblica Ceca 30
EC - Ecuador 28
AE - Emirati Arabi Uniti 25
AT - Austria 25
IR - Iran 23
MA - Marocco 23
SA - Arabia Saudita 21
VE - Venezuela 20
JO - Giordania 18
KE - Kenya 18
NP - Nepal 18
RO - Romania 18
PH - Filippine 15
TH - Thailandia 15
CH - Svizzera 13
MD - Moldavia 12
JM - Giamaica 11
UZ - Uzbekistan 11
AZ - Azerbaigian 10
EU - Europa 10
PY - Paraguay 10
SY - Repubblica araba siriana 10
TN - Tunisia 10
DO - Repubblica Dominicana 9
HU - Ungheria 9
IL - Israele 9
CR - Costa Rica 8
RS - Serbia 8
BH - Bahrain 7
DZ - Algeria 7
GR - Grecia 7
AL - Albania 6
HN - Honduras 6
NG - Nigeria 6
PE - Perù 6
PT - Portogallo 6
AO - Angola 5
ET - Etiopia 5
GH - Ghana 5
HR - Croazia 5
KG - Kirghizistan 5
LB - Libano 5
MT - Malta 5
SK - Slovacchia (Repubblica Slovacca) 5
BO - Bolivia 4
CI - Costa d'Avorio 4
CY - Cipro 4
DK - Danimarca 4
GA - Gabon 4
LV - Lettonia 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
IS - Islanda 3
KH - Cambogia 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
OM - Oman 3
Totale 22.313
Salva come PNG Salva come JPEG
Città #
Ashburn 1.264
Singapore 1.030
Santa Clara 1.023
Dublin 828
Fairfield 636
Hong Kong 599
Chandler 592
San Jose 524
Dallas 489
Southend 420
Hefei 337
Houston 303
Council Bluffs 301
Woodbridge 294
Beijing 281
Nyköping 259
Seattle 256
Wilmington 241
Ann Arbor 227
New York 222
Dearborn 215
London 211
Ho Chi Minh City 204
Los Angeles 191
Cambridge 176
Helsinki 166
Modena 159
The Dalles 150
Jacksonville 147
Hanoi 144
Milan 141
Seoul 135
Chicago 133
Jakarta 111
Munich 107
Shanghai 95
Rome 90
Lauterbourg 89
Bologna 82
San Diego 74
Moscow 73
Fremont 62
Sofia 61
Princeton 60
Frankfurt am Main 58
Buffalo 56
Orem 52
Redwood City 52
São Paulo 52
Tokyo 47
Eugene 44
Columbus 42
Dong Ket 41
Salt Lake City 40
Warsaw 39
Baghdad 38
Izmir 37
Phoenix 36
Guangzhou 34
Bremen 33
Toronto 33
Enfield 32
Parma 30
Reggio Emilia 30
Brooklyn 29
Mumbai 29
San Giuliano Milanese 26
Da Nang 25
Elk Grove Village 25
Falls Church 25
Paris 25
Portsmouth 25
Tampa 25
Redondo Beach 24
Lawrence 22
Nuremberg 22
Asyut 21
Boardman 21
Brussels 21
Denver 21
Montreal 21
Santiago 21
Atlanta 20
Chennai 19
Haiphong 19
Amsterdam 18
Dhaka 18
Florence 18
Johannesburg 18
Kent 18
Mexico City 18
Genoa 17
Miami 17
Naples 17
Palermo 17
Poplar 17
Turku 17
Des Moines 16
Belo Horizonte 15
Brno 15
Totale 14.770
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 630
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 455
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 425
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 403
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 398
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 397
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 392
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 380
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 375
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 372
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 366
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 363
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 362
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 357
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 355
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 353
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 345
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 344
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 331
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 330
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 320
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 317
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 317
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 316
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 313
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 312
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 311
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
Immune characterization of breast cancer metastases: prognostic implications. 309
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 305
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 304
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 300
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 291
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 290
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 288
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 287
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 283
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 280
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 274
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 271
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 269
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 265
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 261
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 260
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 259
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 257
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 257
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 254
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 252
The role of exosomes in breast cancer diagnosis 239
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 237
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 235
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 235
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 234
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 229
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 226
Lapatinib and renal impairment: a case report 226
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 226
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 222
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 218
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 215
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 212
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 210
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 206
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 199
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 196
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 194
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 193
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 191
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 178
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 170
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 169
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 165
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 162
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 154
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 154
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 145
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 137
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 130
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 105
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 96
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer 11
Totale 22.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.305
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.305
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20254.164 141 53 127 268 814 592 319 257 410 286 335 562
2025/20268.506 567 251 924 798 1.108 510 1.047 441 806 789 712 553
2026/2027233 233 0 0 0 0 0 0 0 0 0 0 0
Totale 22.508